Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma have?
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma has 160 citations in the OpenAlex counts ScholarIQ stores.
When was Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma published?
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma has 2013 year in the ScholarIQ index.
What is the open-access status of Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma?
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma has bronze oa status in the ScholarIQ index.
What is the DOI of Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma?
The DOI for Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma is on the source record.
What is the PMID of Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma?
The PMID for Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma is on the source record.
What is the OpenAlex record for Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma?
The OpenAlex for Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma is on the source record.